{"id":"NCT00048932","sponsor":"Bristol-Myers Squibb","briefTitle":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-12","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2002-11-13","resultsPosted":"2011-05-03","lastUpdate":"2011-11-24"},"enrollment":1795,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Double-blind Abatacept","otherNames":["Orencia","BMS-188667"]},{"type":"DRUG","name":"Double-blind Placebo","otherNames":[]},{"type":"DRUG","name":"Open-label Abatacept","otherNames":["Orencia","BMS-188667"]}],"arms":[{"label":"Double-blind abatacept","type":"ACTIVE_COMPARATOR"},{"label":"Double-blind Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-label Abatacept","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.","primaryOutcome":{"measure":"Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation","timeFrame":"Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication","effectByArm":[{"arm":"Abatacept (ABA)","deltaMin":5,"sd":null},{"arm":"Placebo (PLA)","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":["29329602"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":425,"n":1184},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","NASOPHARYNGITIS","DIARRHOEA","NAUSEA"]}}